On 15 May, it was announced that Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or the “Company”; stock code: 600196-SH, 02196-HK), a leading pharmaceutical and healthcare company in the PRC, would be included the MSCI China Index as a constituent stock, effective after the market-close on 30 May 2014.
As an index compiled by Morgan Stanley Capital International (MSCI) to track China –Concept stock performance, the MSCI China Index normally select stocks with decent capitalization and good liquidity. With the aim to reflect reality and mirror the market performance in real time, the constituents of MSCI Indexes are adjusted on quarterly basis in February, May, August and November. The adjustments in May and November are made in half-year, theygive consideration to a wider range of factors , hence their influence are greater than those made in February and August.

The inclusion into the MSCI China Index fully indicates the market’s confidence in Fosun Phama’s brand and its growth potential. It is believed that such a inclusion could further enhance the Company’s reputation and standing in the international capital market.

It’s learned that in addition to Fosun Pharma, other additions to the MSCI China Index include China Everbright Bank (06818.HK), China Huishan Dairy Holdings Company Limited (06863.HK) and Kingsoft Corporation Limited (03888.HK).